Laboratory monitoring of biologic therapies

Clinical and Experimental Rheumatology

Volumn 23, Issue 5 SUPPL. 39, 2005, Pages

  Cush, John J ^a,b   Yazici, Yusuf ^c  

^a PRESBYTERIAN HOSPITAL OF DALLAS   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adverse events; Biologics; Monitoring; Side effects; TNF inhibitors

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUBERCULIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR; BIOLOGICAL RESPONSE MODIFIER; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; BIOLOGICAL THERAPY; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CYTOPENIA; DEMYELINATING DISEASE; DRUG MONITORING; HUMAN; LABORATORY TEST; LIVER FAILURE; LUPUS LIKE SYNDROME; LYMPHOMA; OPPORTUNISTIC INFECTION; PATIENT MONITORING; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SIDE EFFECT; TUBERCULIN TEST; TUBERCULOSIS; BLOOD CELL COUNT; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; FUNCTION TEST; HEALTH ASSESSMENT QUESTIONNAIRE; HYPERTRANSAMINASEMIA; IMMUNOMODULATION; LIVER FUNCTION TEST; PATIENT RISK; PRACTICE GUIDELINE; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOLOGIST; SEDIMENTATION RATE; SEROLOGY; THORAX RADIOGRAPHY; DRUG ANTAGONISM; IMMUNOLOGY; METHODOLOGY; RHEUMATOLOGY;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; DRUG MONITORING; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR; RHEUMATOLOGY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33644799488     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. CUSH JJ: Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus. Clin Exp Rheumatol 2004; 22 (Suppl 35): S141-S147.
2. PINCUS T, KAVANAUGH A, SOKKA T: Benefit/risk of therapies for rheumatoid arthritis: underestimation of the "side effects" or risks of RA leads to underestimation of the benefit/risk of therapies. Clin Exp Rheumatol 2004; 22 (Suppl 35): S2-S11.
3. KAVANAUGH A, VAN VOLLENHOVEN RF, PINCUS T: Benefit/risk of new drugs for rheumatoid arthritis. Clin Exp Rheumatol 2004; 22 (Suppl 35): S1-S150.
4. CUSH JJ, KAVANAUGH AF: FDA Meeting March 2003: Update on the safety of new drugs for rheumatoid arthritis. Part I. The risk of lymphoma with rheumatoid arthritis (RA) and TNF inhibitors. Hotline. American College of Rheumatology. April 2003 http://www.rheumatology.org/research/hotline/0303TNFL.htm
5. KAVANAUGH AF, MATTESON E, CUSH JJ: FDA Meeting March 2003: Update on the Safety of New Drugs for Rheumatoid Arthritis. Part II: CHF, Infection and other Safety Issues. Hotline. American College of Rheumatology. August 2003 http://rheumatology.org/publications/hotline/0803chf.asp?aud=mem
6. CUSH JJ: Biologic drug use: USA perspectives on indications and monitoring. Ann Rheum Dis 2005 (in press).
7. DE BANT M, SIBILIA J, LE LOET X et al.: Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7: R545-51.
8. YAZICI Y, ERKAN D, PAGET SA: Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra associated adverse events. Arthritis Rheum 2003: 48; 2769-72.